Vitalis Group SA — Exit Strategy
The exit pathways — strategic sale, secondary and IPO — and the value-realisation routes available to Series A investors over the planning horizon.
Section 22 · Business Plan
Exit Strategy
The exit pathways — strategic sale, secondary and IPO — and the value-realisation routes available to Series A investors over the planning horizon.
The Company’s board and management are committed to delivering a
competitive, well-timed liquidity event for Series A investors. Three
credible exit pathways are presented below, with a Year 7 JSE IPO as the
base-case route. Strategic and financial-buyer trade-sale interest is
expected to develop in parallel from Year 5 onwards.
22.1 Primary Exit Path — JSE Listing (Year 7 Base Case)
A primary listing on the Johannesburg Stock Exchange Main Board in
Year 7 is the base case. The Company will have a five-year audited track
record by Year 7, three full years of profitability, and a documented
compliance and governance history. Subject to market conditions, a
secondary listing on a major international exchange (LSE or NYSE ADR)
may be added as the SADC expansion matures (post-Year 9).
| IPO Parameter | Indicative Position |
|---|---|
| Target listing date | Q3 Year 7 |
| Listing venue | JSE Main Board, FTSE/JSE All Share index inclusion at IPO+30 days |
| Indicative valuation range | R18-22 Bn (Base), R22-26 Bn (Upside) |
| Free-float at IPO | 20-25% (primary + Series A secondary) |
| Primary issuance | R1.0-1.5 Bn new equity (growth capital and selective debt paydown) |
| Series A secondary sell-down | 30-50% at IPO; remainder under 6-12 month lock-up |
| Bookrunners (expected) | 2-3 mandated South African investment banks plus one international |
| Pre-IPO advisor | Mandated 18 months before listing (Month 54) |
| Compliance window | Three full years JSE Main Board listing requirements satisfied by Yr 6 |
22.2 Alternative Exit Path — Trade Sale (Year 5-7)
A strategic trade sale to a domestic or international
financial-services group represents a credible alternative if the IPO
market is unreceptive or if a strategic premium is achievable. Potential
trade buyers include international integrated insurance and
asset-management groups seeking African footprint, large domestic
financial-services groups seeking platform diversification, and embedded
technology / “neo-insurance” platforms.
- Expected EV/EBITDA range: 9x–12x trailing
EBITDA, with a likely strategic premium of 15-25% for the proprietary
behavioural data and platform. - Process timing: A typical sale process runs 8-12
months from mandate to close. - Key buyer types: Domestic financial-services
majors (Sanlam, Old Mutual, FirstRand, Discovery); pan-African insurers
(Allianz Africa, AXA Africa); international insurers entering Africa
(Prudential plc, AIA, Manulife); insurtech platforms (Ping An Health
Tech, Lemonade et al — less likely as full acquirers but possible as JV
or partner)
22.3 Alternative Exit Path — Secondary / Continuation
A partial secondary transaction in Year 5 to a continuation fund or
institutional secondary buyer offers an interim liquidity option for
Series A investors who require an earlier exit. Such transactions can
also serve as a partial dividend recapitalisation to investors while
preserving the long-term IPO option.
22.4 Path Decision Framework
The board will review exit options annually from Year 4 onwards. The
decision framework weighs five factors:
- IPO market receptivity: SA equity issuance conditions, sector P/E
multiples, foreign-investor appetite for SA paper. - Strategic buyer interest level: unsolicited approaches,
peer-group M&A activity, indicative multiples in current trade-sale
precedent transactions. - Operating performance versus plan: combined ratio trajectory,
scale milestones, regulatory rating. - Capital position: ability to fund expansion organically versus
need for incremental capital raise. - Investor liquidity preferences: explicit feedback from Series A
holders, fund life timelines, and continuation needs.
Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of Vitalis Group South Africa (Pty) Ltd.